|
CDH1 intron 2 genotype distributions among DGC cases and controls |
||||||||
| +14184ΔAGGG cases (n = 134) |
+14184ΔAGGG controls (n = 100) |
χ2-test |
OR (95%CI)*,† |
OR (95%CI)*,† |
||||
|
|
||||||||
| +/+ |
+/Δ |
Δ/Δ |
+/+ |
+/Δ |
Δ/Δ |
p |
Δ/Δ vs +/+ |
+/Δ vs +/+ |
| 128 |
4 |
2 |
96 |
3 |
1 |
0.947 |
1.50 (0.13–16.78) |
1.00 (0.21–4.57) |
| 95.5% |
3% |
1.5% |
97% |
1.5% |
1.5% |
14.2% |
2.5% |
|
|
|
||||||||
| +14384C>T cases (n = 134) |
+14384C>T controls (n = 100) |
χ2-test |
OR (95%CI) |
OR (95%CI) |
||||
|
|
||||||||
| CC |
CT |
TT |
CC |
CT |
TT |
p |
TT vs CC |
CT vs CC |
| 130 |
2 |
2 |
98 |
1 |
1 |
0.895 |
1.51 (0.13–16.87) |
1.51 (0.13–16.87) |
| 97.0% |
1.5% |
1.5% |
98.0% |
1.0% |
1.0% |
12.3% |
12.3% |
|
|
|
||||||||
| +37235G>A cases (n = 134) |
+37235G>A controls (n = 100) |
χ2-test |
OR (95%CI) |
OR (95%CI) |
||||
|
|
||||||||
| GG |
GA |
AA |
GG |
GA |
AA |
p |
AA vs GG |
GA vs GG |
| 30 |
56 |
48 |
37 |
50 |
13 |
0.0003 |
4.55 (2.09–9.93) |
1.38 (0.75–2.55) |
| 22.4% |
41.8% |
35.8% |
37.0% |
50.0% |
13.0% |
100% |
40.6% |
|
|
|
||||||||
| +37276T>A cases (n = 134) |
+37276T>A controls (n = 100) |
χ2-test |
OR (95%CI) |
OR (95%CI) |
||||
|
|
||||||||
| TT |
TA |
AA |
TT |
TA |
AA |
p |
AA vs TT |
TA vs TT |
| 65 |
65 |
4 |
46 |
51 |
3 |
0.929 |
0.94 (0.20–4.42) |
0.90 (0.53–1.53) |
| 48.5% |
48.5% |
3.0% |
46.0% |
51.0% |
3.0% |
1.9% |
1.6% |
|
|
|
||||||||
| 49526C>G cases (n = 134) |
+49526C>G controls (n = 100) |
χ2-test |
OR (95%CI) |
OR (95%CI) |
||||
|
|
||||||||
| CC |
CG |
GG |
CC |
CG |
GG |
p |
GG vs CC |
CG vs GG |
| 34 |
82 |
18 |
30 |
58 |
12 |
0.727 |
1.32 (0.55–3.19) |
1.25 (0.69–2.26) |
| 25.4% |
61.2% |
13.4% |
30.0% |
58.0% |
12.0% |
32.2% |
22.5% |
|
|
*OR values are unadjusted. †The percentage below the OR values estimates the power of association for each variant at the corresponding OR level and assuming a significance level of 5%. | ||||||||
Nasri et al. BMC Cancer 2008 8:138 doi:10.1186/1471-2407-8-138 |
||||||||